IRVINE, CA -- (MARKET WIRE) -- September 29, 2006 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine, announced today that it received a letter from the FDA stating that the FDA had completed its review of the Company's response to the Warning Letter dated September 5, 2006. The FDA reported that the Company's response adequately addressed the FDA's concerns. As a result, the Company believes the issues have been fully resolved.
